Aripiprazole augmentation induced hypertension in major depressive disorder: a case report.

摘要

Major depressive disorder (MDD) is the fourth leading cause of global disease, affecting 13-14 million adults in the United States alone (Kessler et al., 2003). The majority of affected individuals respond to medical treatment such as tricydic antidepressants, monoamine oxidase inhibitors, and selective serotonin reuptake inhibitors (SSRIs). However, between 30%-46% of MDD patients are refractive to these treatments and thus require augmentative therapies (Greden, 2001). Positive outcomes in treating MDD have been reported with atypical neuroleptic compounds such as olanza-pine (Trivedi et al., 2009), quetiapine (Bauer et al., 2009), and aripiprazole (Thase et al., 2008). We reported a case of a refractive MDD patient with diabetes mellitus who developed a hypertensive crisis after treatment with duloxetine and aripiprazole.